Peptides by condition · Hormones and sexual health
Peptides studied for low sexual desire and erectile dysfunction
Checked against our study pages and the FDA labelsPublished by PepVault
Our library holds 7 study pages on low sexual desire and erectile dysfunction: 7 in people (4 of them meta-analyses or randomized trials). They studied 2 compounds, with this many study pages each: PT-141 5 and Melanotan II 2.
What the research on low sexual desire and erectile dysfunction looks like
Two sexual problems have peptide research in people: low sexual desire that causes distress in women, called hypoactive sexual desire disorder (HSDD), and erectile dysfunction in men. The peptides studied act on melanocortin receptors in the brain, which sets them apart from the erection pills that act on blood flow.
The desire trials asked women to log satisfying sexual events and rate desire on questionnaires, against placebo. The erection studies tracked erections over several hours with RigiScan, a device that records their firmness.
Side effects matter as much as benefit here: nausea and flushing were common, and some people stopped because of them. The erection studies were small and early, with a handful of men each.

The 7 studies, by compound
Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.
PT-141
5 in peopleFor low sexual desire and erectile dysfunction, 5 of our study pages are filed under PT-141: 1 meta-analysis, 3 randomized trials and 1 systematic review in people. The largest in people pooled 3,500 people and was published in 2022. They were published from 2016 to 2022, in J Sex Res, J Womens Health (Larchmt), Womens Health (Lond) and J Sex Med.
FDA-approved, with a use tied to low sexual desire and erectile dysfunction on its label: Vyleesi (injection) for low sexual desire that causes marked distress (acquired, generalized hypoactive sexual desire disorder) in premenopausal women; its label says it is not for men or to enhance sexual performance.
- Meta-analysis in people · 2021PT-141: side-effect dropouts far higher than placebo in re-analysis
- Randomized trial in people · 1,202 people · 2022PT-141: desire gains over placebo held across RECONNECT subgroups
- Randomized trial in people · 327 people · 2016PT-141: +0.7 vs +0.2 satisfying sexual events a month at 12 weeks
- Randomized trial in people · 2019PT-141: more responders than placebo at 1.75 mg on all 7 measures
- Systematic review in people · 3,500 people · 2022PT-141: nausea in 40.0% vs 1.3% on placebo in phase 3 safety data
Melanotan II
2 in peopleFor low sexual desire and erectile dysfunction, 2 of our study pages are filed under Melanotan II: 2 clinical trials in people. The largest in people enrolled 20 people and was published in 2000. They were published from 1998 to 2000, in Int J Impot Res and J Urol.
Melanotan II has no FDA-approved product: Drugs@FDA lists no application for it.
- Clinical trial in people · 20 people · 2000Melanotan II: erections in 17 of 20 men with erectile dysfunction
- Clinical trial in people · 10 people · 1998Melanotan II: erections in 8 of 10 men with psychogenic ED
Side by side
For the 2 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).
| Compound | In people | Animals or cells | Largest in people | FDA |
|---|---|---|---|---|
| PT-141 | 5 | 0 | 3,500 | Approved, a use tied to it |
| Melanotan II | 2 | 0 | 20 | Not approved |
- In people
- 5
- Animals or cells
- 0
- Largest in people
- 3,500
- FDA
- Approved, a use tied to it
- In people
- 2
- Animals or cells
- 0
- Largest in people
- 20
- FDA
- Not approved
What the studies did not show
Each study page names its own limits. These are the questions still open, in the study pages’ words.
- PT-141: side-effect dropouts far higher than placebo in re-analysisThis is one author's re-analysis of two existing trials, not a new trial. Treating trial completion plus joining the follow-up study as a preference for placebo is an indirect measure.
- PT-141: desire gains over placebo held across RECONNECT subgroupsThis splits two trials into smaller subgroups, and a few subgroups, including desire in hormonal birth control users, did not reach a significant result. It covers the 24-week controlled phase, not the longer open-label extension.
- Melanotan II: erections in 17 of 20 men with erectile dysfunctionThis was a small trial of 20 men, with each response measured over only 6 h after dosing. It doesn't show what happens with repeated or long-term use, or how safe that would be.
- Melanotan II: erections in 8 of 10 men with psychogenic EDThis was a very small trial in only 10 men, with each response measured over a single 6-hour window. It included only men without a physical cause for their erectile dysfunction, so it doesn't show results in other groups or with longer use.
This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.
Questions
Which peptides have been studied for low sexual desire and erectile dysfunction?
Our 7 study pages on low sexual desire and erectile dysfunction are filed under 2 compounds, with this many each: PT-141 5 and Melanotan II 2. PT-141 has the most.
Have any been tested in people with low sexual desire and erectile dysfunction?
Yes: all 7 were in people, 4 of them meta-analyses or randomized trials (PT-141). The largest pooled 3,500 people: “PT-141: nausea in 40.0% vs 1.3% on placebo in phase 3 safety data” (2022).
Is any peptide FDA-approved for low sexual desire and erectile dysfunction?
Yes, with a use tied to low sexual desire and erectile dysfunction on their FDA labels: PT-141 as Vyleesi. 1 other compound here with an FDA record has no use tied to it.
How large were the studies in people on low sexual desire and erectile dysfunction?
Of the 7 in people, 5 give their size on our pages: 2 had 1,000 people or more, 1 had 100 to 999 and 2 had fewer than 100. The largest, a systematic review from 2022, pooled 3,500.
What is the newest study on low sexual desire and erectile dysfunction here?
Of our study pages on low sexual desire and erectile dysfunction, the newest is “PT-141: desire gains over placebo held across RECONNECT subgroups”, a randomized trial in people published in 2022.
How this page was built
A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.
Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.